MRP-L32 Inhibitors

Inhibits mitochondrial protein synthesis by binding to the peptidyl transferase center of the mitochondrial ribosome, where MRP-L32 is a component. By directly inhibiting the ribosomal function, it prevents MRP-L32 from performing its role in mitochondrial protein synthesis.

Known to bind to the 30S subunit of bacterial ribosomes and can also affect mitochondrial ribosomes. Its binding action could inhibit the protein synthesis machinery where MRP-L32 functions, thereby inhibiting its activity.

A tetracycline antibiotic that can inhibit mitochondrial protein synthesis. Since MRP-L32 is a mitochondrial ribosomal protein, doxycycline's action in inhibiting the mitochondrial ribosome would inhibit the function of MRP-L32.

While primarily targeting bacterial ribosomes, azithromycin has been shown to affect mitochondrial ribosome function. Since MRP-L32 is a component of the mitochondrial ribosome, its function would be inhibited by the action of azithromycin.

An antibiotic that can bind to the peptidyl transferase loop of ribosomal RNA, potentially inhibiting mitochondrial ribosomes as well. This action would inhibit the function of mitochondrial ribosomal proteins, including MRP-L32.

Known to bind to ribosomes and inhibit protein synthesis. Although it mainly targets bacterial ribosomes, cross-reaction with mitochondrial ribosomes can occur, inhibiting the function of MRP-L32 as part of the mitochondrial protein synthesis apparatus.

A tetracycline derivative that inhibits protein synthesis by binding to the 30S ribosomal subunit. If it affects mitochondrial ribosomes, it would inhibit the synthesis of mitochondrial proteins, which includes the function of MRP-L32.

Binds to the 50S subunit of bacterial ribosomes and may similarly affect mitochondrial ribosomes, potentially inhibiting the protein synthesis process in which MRP-L32 is involved.